• Home
  • All News Articles
  • Rethink the Strip: De-adoption of Glucose Monitoring for Non-Insulin Treated Type 2 Diabetes in Primary Care

Project Summary
PCORI funds Dissemination and Implementation projects to increase awareness and promote the use of PCORI research findings to improve healthcare practices and health outcomes. This project is proposing to conduct dissemination and implementation activities for the results of the research project:Does Daily Self-Monitoring of Blood Sugar Levels Improve Blood Sugar Control and Quality of Life for Patients with Type 2 Diabetes Who Do Not Use Insulin? -- The Monitor Trial.

1. What research finding is this project disseminating or implementing?
With funding from PCORI, we implemented the largest pragmatic trial to date of self-monitoring of blood glucose (SMBG) in primary care patients with non-insulin treated type 2 diabetes mellitus (NIT T2DM) in the US. Among 450 adults over the age of 30 with NIT T2DM drawn from 15 North Carolina primary-care practices, the MONITOR Trial examined whether SMBG impacts A1c, health-related quality of life, or key adverse events, such as hypoglycemic frequency, health care utilization, and insulin initiation. Patients were randomly assigned to three trial arms: no SMBG, once-daily SMBG, and once-daily SMBG with enhanced patient feedback, including automatic tailored messages delivered via the glucose meter. We found no clinically or statistically significant differences at 1 year in A1c between patients with NIT T2DM who performed SMBG and those who did not. Similarly, no differences were found for health-related quality of life or key adverse events. In short, this large, targeted, randomized study found no evidence that SMBG, even when enhanced with messaging, leads to improvements in key outcomes. Based on our findings, we propose to disseminate and implement a multi-component de-adoption strategy targeted at primary care practices, healthcare providers, patients, and payers.

2. Why is this research finding important?
Ours and others’ research shows that SMBG is a low-value test that should not be routine for patients with NIT T2DM. De-adoption of SMBG can minimize the associated costs, both monetary and personal, of SMBG overtreatment. De-adoption may also provide more time and resources for clinicians and patients to focus on treatments with more proven effectiveness for NIT T2DM. Successful de-adoption can positively affect end-users by helping primary care clinicians and patients make more patient-centered decisions that reflect their preferences, needs, and values.

3. What is the goal of the D&I project?
The program, titled Rethink the Strip, delivers a multi-component de-adoption strategy to primary care practices, healthcare providers, patients, and payers. The primary objective is to engage a broad group of stakeholders to implement a patient-centered approach to the de-adoption of SMBG among NIT T2DM patients (Aim 1). Using a repeated measures design, we will evaluate the effectiveness and impact of Rethink the Strip (Aim 2). Using lessons learned, we will finalize and package Rethink the Strip for nationwide dissemination (Aim 3).

4. What is the project team doing?
We will work with six external change agents to implement five intervention components at 20 sites. We selected components from existing taxonomies of implementation strategies that target the multilevel factors influencing SMBG, and have the strongest evidence base for effectiveness. The final Rethink the Strip de-adoption strategy includes three practice components delivered directly to the practices (practice facilitation, audit and feedback, practice champions) and two directed to the health system generally (educational meetings, print and electronic materials). In our two-phase roll-out, we will implement the first three components in three practices for six months (Phase 1). Following stakeholder input and discussion of Phase 1 results, we will refine the intervention and conduct the full roll-out to the remaining 17 sites for 18 months (Phase 2). We will then finalize Rethink the Strip for broad-scale distribution. The final kit of successful strategies used in his proposal is expected to include the steps used for the audit and feedback approach, practice facilitation approaches, methods for engaging stakeholders, and materials and handouts used.

5. How will the project team evaluate its D&I activities?
Our evaluation will use the RE-AIM evaluation framework, assessing adoption by primary care practices, providers, and care managers; implementation fidelity; and patient reach. The process evaluation will also indirectly assess the potential reach of Rethink the Strip through its effects on participating practices and their providers (outcomes). Formal outcome evaluation will assess the intervention’s impact on providers’ knowledge, attitude, and self-efficacy, and the prescription of test strips.

Reach:We will use counts of the number of providers and diabetes educators attending educational and practice facilitator sessions, as well as NIT T2DM patients per practice who present for visits with their health care provider.

Effectiveness: We will survey providers and diabetes educators on knowledge and attitudes about SMBG de-adoption. Test strip prescription levels will be assessed at baseline and every three months for 18 months.

Adoption: We will examine characteristics of providers who did and did not reduce test strip prescribing, practices agreeing versus declining to participate, and providers who and do not participate in educational sessions. We will also meet with BCBS care managers to assess attendance rates and discussion of de-adoption.

Implementation: Fidelity, feasibility, and acceptability of Rethink the Strip will be evaluated via attendance logs, provider surveys, and provider/patient/diabetes educator interviews and focus groups. Brief providers surveys will be administered after each educational meeting. We will also conduct semi-structured interviews with 20 NIT T2DM patients exposed to Rethink the Strip, asking about any educational materials they received or discussions they held with their doctors. We will also conduct five focus groups with providers and one focus group with diabetes educators, discussing the usefulness of the educational materials and reactions to/experiences with Rethink the Strip.

Maintenance: In addition to our maintenance-related primary outcome of test strip prescriptions at 18 months, we will include interview, survey, and focus group questions on the likelihood of maintaining de-adoption.

Read more on this project at PCORI site.

NC TraCS Institute logo vertical

In partnership with:

Contact Us


Brinkhous-Bullitt, 2nd floor
160 N. Medical Drive
Chapel Hill, NC 27599

919.966.6022
This email address is being protected from spambots. You need JavaScript enabled to view it.

Social


Cite Us


© 2008-2020 The North Carolina Translational and Clinical Sciences (NC TraCS) Institute at The University of North Carolina at Chapel Hill
The content of this website is solely the responsibility of the University of North Carolina at Chapel Hill and does not necessarily represent the official views of the NIH   accessibility | contact